Clinical Trial Update: Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of golimumab in early Axial Spondyloarthritis and its relation to gut inflammation; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: University Ghent | Conditions: Axial Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-11